VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults

NCT02408913 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

140

Enrollment

NIH

Sponsor class

Conditions

Healthy Adult Immune Responses to Vaccine

Interventions

BIOLOGICAL: VRC-EBOMVA079-00-VP (MVA-EbolaZ)
BIOLOGICAL: VRC-EBOADC069-00-VP (cAd3-EBO)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)